Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma

Authors: Lan Yu, Lei Zhou, Shiwu Wu, Xiaomeng Gong, Zhenzhong Feng, Li Ma, Bo Zhu, Nan Yao, Danna Wang, Huiming Dong

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

Presently, CD133 is one of the hottest markers to characterize cancer stem cells and KAI1/CD82 is reported as an important marker for the metastasis and prognosis of many cancers. The purpose of our study is to explore the relationship between cancer stem cells (CSCs) marked by CD133 and KAI1/CD82 expression and the clinicopathological characteristics of patients with laryngeal squamous cell carcinoma (LSCC).

Methods

Immunohistochemical analysis was used to detect the expression of CD133 and KAI1/CD82 in 83 archival surgical specimens of human LSCC and 83 cases of normal laryngeal tissues.

Results

In LSCC, positive rates of 49.4% and 41.0% were obtained for CD133 and KAI1/CD82, respectively. The expression of CD133 in LSCC tissues was significantly higher than that in normal tissues (P < 0.001), and the expression of CD133 was positively associated with pTNM stage (P = 0.005), pathological grade (P = 0.001), and lymph node metastasis (P < 0.001). The reduced expression of KAI1/CD82 was present in LSCC tissues. The positive rate of KAI1/CD82 expression was negatively correlated with pTNM stage (P = 0.014), pathological grade (P < 0.001), and lymph node metastasis (P = 0.007). A correlation analysis showed that there was a negative relationship between the expression of CD133 and KAI1/CD82 protein in LSCC tissues (P < 0.001). By Kaplan-Meier analysis, the expression of CD133 was negatively correlated with overall survival (OS) (log-rank = 40.949, P < 0.001) and disease-free survival (DFS) (log-rank = 39.307, P < 0.001) time of LSCC. The expression of KAI1/CD82 was positively correlated with OS (log-rank = 40.279, P < 0.001) and DFS (log-rank = 39.271, P < 0.001) time of LSCC. Cox regression analysis: the expression of CD133 and KAI1/CD82, and pTNM stages were independent prognostic factors of LSCC (P < 0.05).

Conclusions

Thus the detection of CD133 and KAI1/CD82 proteins may be used as a potential indicator of LSCC prognosis.

Available only for authorised users

Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed

Burkert J, Wright NA, Alison MR: Stem cells and cancer: an intimate relationship. J Pathol. 2006, 209: 287-297. 10.1002/path.2016.CrossRefPubMed

Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 2007, 58: 267-284. 10.1146/annurev.med.58.062105.204854.CrossRefPubMed

Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006, 12: 895-904. 10.1038/nm1469.CrossRefPubMed

Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997, 90: 5013-5021.PubMed

Wu Y, Wu PY: CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009, 18: 1127-1134. 10.1089/scd.2008.0338.CrossRefPubMed

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 2007, 445: 111-115. 10.1038/nature05384.CrossRefPubMed

Schneider M, Huber J, Hadaschik B, Sieqers G, Fiebig HH, Schueler J: Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 2012, 12: 96-10.1186/1471-2407-12-96.PubMedCentralCrossRefPubMed

Zhao P, Lu Y, Jiang X, Li X: Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011, 102: 1107-1111. 10.1111/j.1349-7006.2011.01894.x.CrossRefPubMed

10.

Di Bonito M, Collina F, Cantile M, Camerlingo R, Cerrone M, Marra L, Liguori G, Pirozzi G, Botti G: Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast carcinoma: a correlative study between qRT-PCR, flow-cytometric and immunohistochemistry analysis. J Breast Cancer. 2012, 15: 15-23. 10.4048/jbc.2012.15.1.15.PubMedCentralCrossRefPubMed

11.

Wang T, Ong CW, Shi J, Srivastava S, Yan B, Cheng CL, Yong WP, Chan SL, Yeoh KG, Iacopetta B, Salto-Tellez M: Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer. 2011, 105: 658-665. 10.1038/bjc.2011.287.PubMedCentralCrossRefPubMed

12.

Yang ZL, Zheng Q, Yan J, Pan Y, Wang ZG: Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J Gastroenterol. 2011, 17: 932-937. 10.3748/wjg.v17.i7.932.PubMedCentralCrossRefPubMed

13.

Brescia P, Richichi C, Pelicci G: Current strategies for identification of glioma stem cells: adequate or unsatisfactory?. J Oncol. 2012, 2012: 376894-PubMedCentralCrossRefPubMed

14.

Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH: Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer. 2011, 117: 2970-2985. 10.1002/cncr.25869.CrossRefPubMed

15.

Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova K, Klein J, Grygarkova I, Kolek V: Identification of CD133+/Nestin + putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010, 154: 321-326. 10.5507/bp.2010.048.CrossRefPubMed

16.

Yu XH, Xu LB, Zeng H, Zhang R, Wang J, Liu C: Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2011, 10: 620-625. 10.1016/S1499-3872(11)60105-7.CrossRefPubMed

17.

Kordes C, Sawitza I, Müller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Häussinger D: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007, 352: 410-417. 10.1016/j.bbrc.2006.11.029.CrossRefPubMed

18.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE: ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011, 6: e20636-10.1371/journal.pone.0020636.PubMedCentralCrossRefPubMed

19.

Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, Adams D, Jiang Z, Languino LR: CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res. 2010, 2: 135-144.PubMedCentralPubMed

20.

Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, Wang L, Guo Y, Wang Z, Yan Q, Huang G: CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 2011, 11: 320-10.1186/1471-2407-11-320.PubMedCentralCrossRefPubMed

21.

Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995, 268: 884-886. 10.1126/science.7754374.CrossRefPubMed

22.

Malik FA, Sanders AJ, Jiang WG: KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol. 2009, 24: 519-530.PubMed

23.

Lazo PA: Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 2007, 98: 1666-1677. 10.1111/j.1349-7006.2007.00584.x.CrossRefPubMed

24.

Miranti CK: Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal. 2009, 21: 196-211. 10.1016/j.cellsig.2008.08.023.CrossRefPubMed

25.

Malik FA, Sanders AJ, Kayani MA, Jiang WG: Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genomics Proteomics. 2009, 64: 205-213.

26.

Yáñez-Mó M, Barreiro O, Gordon-Alonso M, Sala-Valdés M, Sánchez-Madrid F: Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 2009, 19: 434-446. 10.1016/j.tcb.2009.06.004.CrossRefPubMed

27.

Liu W, Iiizumi-Gairani M, Okuda H, Kobayashi A, Watabe M, Pai SK, Pandey PR, Xing F, Fukuda K, Modur V, Hirota S, Suzuki K, Chiba T, Endo M, Sugai T, Watabe K: KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancer. J Biol Chem. 2011, 286: 18948-18959.

28.

Goncharuk VN, del-Rosario A, Kren L, Anwar S, Sheehan CE, Carlson JA, Ross JS: Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Ann Diagn Pathol. 2004, 8: 6-16. 10.1016/j.anndiagpath.2003.11.002.CrossRefPubMed

29.

Mooez S, Malik FA, Kayani MA, Rashid R, Zahid A, Khan A: Expressional alterations and transcript isoforms of metastasis suppressor genes (KAI1 and KiSS1) in breast cancer patients. Asian Pac J Cancer Prev. 2011, 12: 2785-2791.PubMed

30.

Wu DH, Liu L, Chen LH, Ding YQ: KAI1 gene expression in colonic carcinoma and its clinical significances. World J Gastroenterol. 2004, 10: 2245-2249.PubMed

31.

Chen Z, Gu S, Trojanowicz B, Liu N, Zhu G, Dralle H, Hoang-Vu C: Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma. World J Surg Oncol. 2011, 9: 43-10.1186/1477-7819-9-43.PubMedCentralCrossRefPubMed

32.

Guo C, Liu QG, Zhang L, Song T, Yang X: Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2009, 8: 389-396.PubMed

33.

Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol. 2009, 181: 2305-2311. 10.1016/j.juro.2009.01.003.CrossRefPubMed

34.

Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed

35.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432: 396-401. 10.1038/nature03128.CrossRefPubMed

36.

O’Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445: 106-110. 10.1038/nature05372.CrossRefPubMed

37.

Rosen JM, Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science. 2009, 324: 1670-1673. 10.1126/science.1171837.PubMedCentralCrossRefPubMed

38.

Martins-Neves SR, Lopes AO, do Carmo A, Paiva AA, Simões PC, Abrunhosa AJ, Gomes CM: Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer. 2012, 12: 139-10.1186/1471-2407-12-139.PubMedCentralCrossRefPubMed

39.

Chen L, Kasai T, Li Y, Sugii Y, Jin G, Okada M, Vaidyanath A, Mizutani A, Satoh A, Kudoh T, Hendrix MJ, Salomon DS, Fu L, Seno M: A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One. 2012, 7: e33544-10.1371/journal.pone.0033544.PubMedCentralCrossRefPubMed

40.

Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008, 8: 755-768. 10.1038/nrc2499.CrossRefPubMed

41.

Muneyuki T, Watanabe M, Yamanaka M, Shiraishi T, Isaji S: KAI1/CD82 expression as a prognostic factor in sporadic colorectal cancer. Anticancer Res. 2001, 21: 3581-3587.PubMed

42.

Shiwu W, Lan Y, Wenqing S, Lei Z, Yisheng T: Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer. Arch Iran Med. 2012, 15: 707-712.PubMed

43.

Fessler E, Dijkgraaf FE, Melo FD, Medema JP: Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?. Cancer Lett. 2013, 341: 97-104. 10.1016/j.canlet.2012.10.015.CrossRefPubMed

44.

Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Büchler MW, Herr I: Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One. 2012, 7: e46391-10.1371/journal.pone.0046391.PubMedCentralCrossRefPubMed

Title: Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma
Authors: Lan Yu
Lei Zhou
Shiwu Wu
Xiaomeng Gong
Zhenzhong Feng
Li Ma
Bo Zhu
Nan Yao
Danna Wang
Huiming Dong
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-118

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Soft tissue perineurioma of the tongue: report of a case and review of the literature

A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer

Collision tumor with inflammatory breast carcinoma and malignant phyllodes tumor: a case report and literature review

A mixture of carcinoid tumors, extensive neuroendocrine proliferation, and multiple pulmonary sclerosing hemangiomas

Iodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer

Prognostic analysis of gastric gastrointestinal stromal tumor with synchronous gastric cancer